(redirected from C1 inhibitor)
Also found in: Dictionary, Medical, Legal, Encyclopedia.
Graphic Thesaurus  🔍
Display ON
Animation ON
  • noun

Antonyms for inhibitor

a substance that retards or stops an activity

References in periodicals archive ?
Ozellikle C1 inhibitor eksikligi ile iliskili HAE'da ve ADE inhibitorlerine bagli olusan tekrarlayici AE'da daha fazla gorulen laringeal odeme bagli asfiksi ise olgularin %25-40'inda olumle sonuclanabilir (7).
In type 3 HAE, levels and activity of C1 inhibitor levels are normal, but a mutation coding for factor 12 leads to over-production of kallikrein and hence bradykinin (9).
Emergency treatment of acute attacks in hereditary angioedema due to C1 inhibitor deficiency: What is the evidence?
The use of plasma-derived C1 inhibitor in the treatment of hereditary angioedema.
Full session details and data abstracts for the 2015 Bi-Annual Meeting can be found on the C1 Inhibitor Deficiency Workshop website at http://haenet2015.
People suffering from this condition have naturally low levels of C1 inhibitor, which can result in episodes of severe swelling, similar to an allergic reaction.
Serum C1 inhibitor ve C4 duzeyleri cok dusuk olarak tespit edi-len olgumuza, annesine ve ablasina HA tanisi konuldu.
Tonsillectomy in a patient with hereditary angioedema after prophylaxis with C1 inhibitor concentrate.
The data analyzed are from placebo-controlled and open-label clinical studies conducted with the investigational drug RHUCIN([R]) (recombinant human C1 inhibitor, or C1INH) in patients with hereditary angioedema (HAE).
2 - reagents for tests performed by radial immunodiffusion1 C1 inhibitor plasma - 150 tests
These data were presented in a poster entitled, Quality of Life in Patients with Hereditary Angioedema Receiving Nanofiltered C1 Inhibitor for Prophylaxis: Results of a Randomized, Placebo-Controlled, Crossover Study, by William Lumry, MD, FAAAI, FACAAI, et al.
NASDAQ: SNTS) and biotech company Pharming Group NV (NYSE Euronext: PHARM) today announced that a retrospective analysis of integrated efficacy data from patients with Hereditary Angioedema (HAE) undergoing treatment with the investigational drug RHUCIN([R]) (recombinant human C1 inhibitor, or C1INH) for acute attacks of HAE will be presented in an oral presentation at the 2011 Annual Meeting of the American College of Allergy, Asthma & Immunology (ACAAI) in Boston, MA on November 6, 2011.
HAE patients have a defect in the gene that controls production of a protein found in the blood vessels, called C1 inhibitor or C1-INH.
RUCONEST (INN conestat alfa) is a recombinant version of the human protein C1 inhibitor (C1INH).